GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to risvutatug rezetecan, its investigational B7-H3-targeted antibody-drug conjugate ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Pegvisomant, developed by professor John Kopchick in 1987, shows potential to make treatment-resistant lung cancer cells more ...

Gilead Sciences has partnered with digital health company Manta Cares to get tools for navigating lung and breast cancer care ...

SCLC diagnosis involves imaging, biopsies, and lab tests to assess tumor spread and guide treatment decisions. Treatment options vary by stage, with surgery, chemotherapy, radiation, and immunotherapy ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...